In the absence of effective antiviral chemotherapy and still in the context of emerging
vaccines for severe acute respiratory syndrome-CoV-2 infections, passive immunotherapy …

For over a century, transfusion of convalescent plasma from recovered individuals has been
tried as a therapeutic approach when a novel pathogen emerges. As the world awaits SARS …

The epidemic of corona virus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome Coronavirus 2 and its variants of concern (VOCs) has been ongoing for over 3 …

The use of passive immunotherapy, either as plasma or purified antibodies, has been
recommended to treat the emerging infectious diseases (EIDs) in the absence of alternative …

Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma
(CP), plasma collected from individuals who have recovered from an infectious disease, has …

Passive immune therapy consists of several different therapies, convalescent plasma,
hyperimmune globulin, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Antibody therapies such as convalescent plasma and monoclonal antibodies have emerged
as major potential therapeutics for coronavirus disease 2019 (COVID-19). Immunoglobulins …

The COVID-19 pandemic has been humbling for the biomedical community, pointing out as
much about what we do not know as what we do. Among these learnings are lessons about …

Passive immunization (passive immunity, passive immunotherapy) consists in the transfer of
specific antibodies to an unprotected individual with the purpose of protecting from infection …

Antiviral passive antibody therapy includes convalescent plasma, hyperimmune globulin,
and monoclonal antibodies. Passive antibodies have proven effective in reducing morbidity …